["{\n\"step_by_step_thinking\": \"The relevant documents mention ProSavin as 'ksavin' or 'SAP', which is used to treat ischemic heart disease. The document [Evaluation of the efficacy of xavin treatment of ischemic heart disease] mentions that the clinical efficacy of the treatment was correlated with risk factors and indices of ECG, central hemodynamics, and spiroergometry. This suggests that ProSavin has been studied in a clinical setting, but there is no specific mention of phase IV clinical trials by 2018.\",\n\"answer_choice\": \"B: no\"\n}"]